MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

Not Applicable
Recruiting
Conditions
Sphenopalatine Block
Chronic Migraine
BOTOX
Interventions
Drug: Sphenopalatine block
First Posted Date
2025-05-16
Last Posted Date
2025-05-16
Lead Sponsor
Cairo University
Target Recruit Count
64
Registration Number
NCT06974617
Locations
🇪🇬

Cairo University, Cairo, Egypt

Efficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis.

Phase 2
Not yet recruiting
Conditions
Base-of-thumb Osteoarthritis
Osteoarthritis
Interventions
Drug: Normal saline (placebo)
First Posted Date
2025-03-30
Last Posted Date
2025-04-18
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
120
Registration Number
NCT06902805
Locations
🇫🇷

Assistance Publique - Hôpitaux de Paris, Service de Rééducation et de Réadaptation de l'Appareil Locomoteur et des Pathologies du Rachis du Pr François Rannou, Hôpital Cochin, Paris, Île-de-France, France

Does Botulinum Toxin Type-A Injection an Effective Way of Relieving Pain in Myofascial Pain Syndrome Patients or Not

Not Applicable
Completed
Conditions
Myofacial Pain Syndromes
Interventions
First Posted Date
2025-03-28
Last Posted Date
2025-04-01
Lead Sponsor
Bursa City Hospital
Target Recruit Count
38
Registration Number
NCT06899438

The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia

Phase 4
Not yet recruiting
Conditions
Cervical Dystonia, Primary
Interventions
First Posted Date
2025-03-20
Last Posted Date
2025-03-20
Lead Sponsor
Western University, Canada
Target Recruit Count
45
Registration Number
NCT06886750

Effect of Blood Flow by Botulinum Toxin Injection for Severe Peripheral Artery Occlusive Disease

Phase 4
Recruiting
Conditions
Chronic Ulcer of Lower Extremity
Wound
Botulinum Toxins, Type A
Blood Circulation
Interventions
First Posted Date
2025-03-17
Last Posted Date
2025-03-17
Lead Sponsor
Yonsei University
Target Recruit Count
15
Registration Number
NCT06878482
Locations
🇰🇷

Yongin Severance Hospital, Yongin-si, Gyeonggi-do, Korea, Republic of

A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)

Phase 1
Recruiting
Conditions
Glabellar Lines
Interventions
First Posted Date
2025-02-19
Last Posted Date
2025-05-07
Lead Sponsor
AbbVie
Target Recruit Count
126
Registration Number
NCT06834789
Locations
🇺🇸

Investigate MD /ID# 270771, Scottsdale, Arizona, United States

🇺🇸

Marcus Facial Plastic Surgery /ID# 270770, Redondo Beach, California, United States

🇺🇸

Skin Research Institute LLC /ID# 270831, Coral Gables, Florida, United States

and more 5 locations

The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment

Phase 2
Active, not recruiting
Conditions
Keloid Scars
Interventions
First Posted Date
2025-02-07
Last Posted Date
2025-02-07
Lead Sponsor
Universitas Padjadjaran
Target Recruit Count
20
Registration Number
NCT06814288
Locations
🇮🇩

Hasan Sadikin General Hospital, Bandung, Jawa Barat, Indonesia

A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants

Phase 3
Active, not recruiting
Conditions
Forehead Lines
Interventions
First Posted Date
2025-01-27
Last Posted Date
2025-04-20
Lead Sponsor
AbbVie
Target Recruit Count
150
Registration Number
NCT06794866
Locations
🇯🇵

Tokai University Hospital /ID# 268496, Isehara, Kanagawa, Japan

🇯🇵

Queen's Square Medical Center, Dermatology and Allergology /ID# 268454, Yokohama-shi, Kanagawa, Japan

🇯🇵

Jun Clinic /ID# 268531, Nagano-Shi, Nagano, Japan

and more 12 locations

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Phase 4
Recruiting
Conditions
Facial Contouring
Interventions
Device: JUVÉDERM
Device: CoolSculpting Elite System
Other: SkinMedica Products
First Posted Date
2025-01-20
Last Posted Date
2025-04-09
Lead Sponsor
AbbVie
Target Recruit Count
100
Registration Number
NCT06783621
Locations
🇺🇸

Center for Dermatology and Dermatologic Surgery /ID# 270390, Washington, District of Columbia, United States

🇺🇸

Marcus Facial Plastic Surgery /ID# 270408, Redondo Beach, California, United States

🇺🇸

Pacific Clinical Innovations /ID# 270414, Vista, California, United States

and more 7 locations

The Clinical Study of Botulinum Toxin Type A Injection in the Treatment of Wilson Disease

Not Applicable
Completed
Conditions
Wilson Disease
Interventions
First Posted Date
2025-01-07
Last Posted Date
2025-01-15
Lead Sponsor
The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Target Recruit Count
60
Registration Number
NCT06762509
Locations
🇨🇳

the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, #117 Meishan Street, Shushan District Hefei 230037, China, Hefei, China

© Copyright 2025. All Rights Reserved by MedPath